Venous valve apparatus, system, and method

Information

  • Patent Grant
  • 9301843
  • Patent Number
    9,301,843
  • Date Filed
    Wednesday, November 10, 2010
    15 years ago
  • Date Issued
    Tuesday, April 5, 2016
    9 years ago
Abstract
A venous valve apparatus, system and method for valve replacement. The valve includes a valve frame, a valve leaflet joined to the valve frame, and a support frame. The valve leaflet includes surfaces defining a reversibly sealable opening for unidirectional flow of a liquid. The support frame meets the valve frame on an axis, where the valve frame and the support frame extend from the axis in an opposing direction. The system further includes a catheter, where the valve can be reversibly joined to the catheter at a location between a proximal end and a distal end of the catheter. The system can be used to deploy the valve from the catheter at a predetermined location.
Description
FIELD OF THE INVENTION

The present invention relates generally to apparatus, systems, and methods for use in the vasculature; and more particularly to venous valve apparatus, systems, and methods for use in the peripheral vasculature.


BACKGROUND OF THE INVENTION

The venous system of the legs uses pumps to help return blood to the heart. These pumps are formed from the combined action of various muscle groups and bicuspid one-way valves within the venous vasculature. Venous valves create one way flow to prevent blood from flowing away from the heart and also serve to reduce hydrostatic pressure in the lower legs. When valves fail, blood can pool in the lower legs resulting in swelling and ulcers of the leg. The absence of functioning venous valves can lead to chronic venous insufficiency. Venous insufficiency is a condition in which the veins fail to return blood efficiently to the heart. This condition usually involves one or more of the deep veins. Symptoms include swelling of the legs and pain in the extremities such as a dull aching, heaviness, or cramping.


Techniques for both repairing and replacing the valves exist, but are tedious and require invasive surgical procedures. Direct and indirect valvuoplasty procedures are used to repair damaged valves. Transposition and transplantation are used to replace an incompetent valve. Transposition involves moving a vein with an incompetent valve to a site with a competent valve. Transplantation replaces an incompetent valve with a harvested valve from another venous site. Valves can be transplanted into the venous system, but current devices are not successful enough to see widespread usage.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate an embodiment of a valve.



FIGS. 2A and 2B illustrate an embodiment of a valve in an open configuration and an exploded view of the valve.



FIG. 3 illustrates an embodiment of a valve in a compressed state.



FIG. 4 illustrates an embodiment of a valve in an open configuration.



FIGS. 5A and 5B illustrate embodiments of elastic regions for valves.



FIG. 6 illustrates an embodiment of a system that includes a valve.



FIG. 7 illustrates an embodiment of a system that includes a valve.





DETAILED DESCRIPTION

Embodiments of the present invention are directed to an apparatus, system, and method for valve replacement. For example, the apparatus can include a valve that can be used to replace an incompetent valve in a body lumen. Embodiments of the valve can include a frame and leaflet material that can be implanted through minimally-invasive techniques into the body lumen near an incompetent valve. Embodiments of the apparatus, system, and method for valve replacement may help to maintain antegrade blood flow, while decreasing retrograde blood flow and reduce hydrostatic pressure in a venous system of individuals having venous insufficiency, such as venous insufficiency in the legs.


The Figures herein follow a numbering convention in which the first digit or digits correspond to the drawing Figure number and the remaining digits identify an element or component in the drawing. Similar elements or components between different Figures may be identified by the use of similar digits. For example, 110 may reference element “10” in FIG. 1, and a similar element may be referenced as 210 in FIG. 2.



FIGS. 1-4 provide illustrations of various embodiments of a valve of the present invention. Generally, valves can be implanted within the fluid passageway of a body lumen, such as for replacement of a valve structure within the body lumen (e.g., a venous valve), to regulate the flow of a bodily fluid through the body lumen in a single direction. Elements shown in the various embodiments herein can be added, exchanged, and/or eliminated so as to provide any number of additional embodiments of a valve.



FIGS. 1A and 1B illustrate one embodiment of a valve 100. Valve 100 includes a valve frame 114, a support frame 118, and valve leaflets 119. Valve frame 114 and support frame 118 of valve 100 meet on an axis 120. As discussed herein, valve frame 114 and support frame 118 extend from axis 120 in an opposing direction and meet so as to form a flexible joint at and/or around axis 120 according to a number of embodiments.


Multiple embodiments exist for valve frame 114 and support frame 118, both of which can include any number of structural configurations. Generally, the valve frame 114 and the support frame 118 can have curved structural configurations, as will be discussed herein. For example, valve frame 114 and support frame 118 can include a first elliptical member 134 and a second elliptical member 138, as illustrated in FIGS. 1 and 2.


The first elliptical member 134 and the second elliptical member 138 meet at a first region 142 and a second region 146, where the first region 142 and the second region 146 are opposite each other across axis 120. The first region 142 and the second region 146 can be located at any number of locations along the first elliptical member 134 and the second elliptical member 138. For example, the first region 142 and the second region 146 can be at or near a minor axis of the first elliptical member 134 and the second elliptical member 138. In an additional embodiment, the first region 142 and the second region 146 can be positioned away from the minor axis of the first elliptical member 134 and the second elliptical member 138.


While the term elliptical member is used herein, other shapes are possible for the structural members that help to form a valve of the present invention. For example, the valve frame 114 and the support frame 118 can include circular members that meet at the first region 142 and the second region 146. In one embodiment, the circular members meet at the first region 142 and the second region 146 at, or about, the diameter of the circular members. In an additional embodiment, the first region 142 and the second region 146 can be positioned away from the diameter of the circular members. Other shapes besides elliptical and circular are also possible.


The first elliptical member 134 and the second elliptical member 138 can also include either a planar or a non-planar configuration, as will be discussed herein. For example, FIGS. 1A and 1B illustrate an embodiment in which the first elliptical member 134 and the second elliptical member 138 have a planar configuration 147. As such, the first elliptical member 134 and the second elliptical member 138 each form a portion of the valve frame 114 and the support frame 118. For example, the first elliptical member 134 and the second elliptical member 138 both include a valve portion 150 and a support portion 154. The valve portion 150 of the first elliptical member 134 and the second elliptical member 138 extend from the first region 142 and the second region 146 to form the valve frame 114. Similarly, the support portion 154 of the first elliptical member 134 and the second elliptical member 138 extend from the first region 142 and the second region 146 to form the support frame 118.


The first elliptical member 134 and the second elliptical member 138 meet at the first region 142 and the second region 146 at an angle 156. In one embodiment, the size of angle 156 can be selected based upon the type of body lumen and the body lumen size in which the valve 100 is to be placed. In an additional embodiment, there can also be a minimum diameter 158 between the first region 142 and the second region 146 that ensures that the first elliptical member 134 and the second elliptical member 138 will have an appropriate expansion force against the inner wall of the body lumen in which the valve 100 is being placed.


Additional factors include, but are not limited to, a longitudinal length 160 and a width 162 of the valve 100. These factors, along with others discussed herein, can be used to provide the angle 156 that is sufficient to ensure that the first elliptical member 134 and the second elliptical member 138 have an appropriate expansion force against an inner wall of the body lumen in which the valve 100 is being placed. For example, the minimum diameter 158 between the first region 142 and the second region 146 and the angle 156 can both be selected to provide an essentially equivalent expansion force on the body lumen 111 at, or around, the first region 142, the second region 146, and by the other portions of the first elliptical member 134 and the second elliptical member 138 that contact the body lumen 111.


The ability of the valve frame 114 and the support frame 118 to form a flexible joint at and/or around axis 120 allows the valve 100 to accommodate changes in body lumen size (e.g., diameter of the body lumen) by increasing or decreasing angle 156. In addition, the valve frame 114 and the support frame 118 also have the ability to flex, as discussed herein, to allow for the distance between the first region 142 and the second region 146 to increase or decrease, thereby further accommodating changes in the body lumen size (e.g., diameter of the body lumen). The valve frame 114 and the support frame 118 can also provide sufficient contact and expansion force with the surface of a body lumen wall to encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen.



FIGS. 2A and 2B provide a further illustration of a valve 200. FIG. 2B illustrates an exploded view of valve 200, where the first elliptical member 234 and the second elliptical member 238 are shown separated so as to better illustrate a non-planar configuration 270 of the elliptical members 234 and 238. In one embodiment, the first elliptical member 234 and the second elliptical member 238 can have a non-planar configuration 270, where the first elliptical member 234 can form the valve frame 214, and the second elliptical member 238 can form the support frame 218. For example, the non-planar configuration 270 of the first elliptical member 234 and the second elliptical member 238 can include a curve 274 at, or near the minor axis 276, to provide for a series of alternating convex curves 278 and concave curves 280. In another embodiment, the curve 274 need not be located at, or about, the minor axis 276 of the first elliptical member 234 and the second elliptical member 238.


The curved structural configuration of the valve frame 214 and the support frame 218 allow for valve 200 to repeatably travel between a collapsed state, as shown in FIG. 3, and an expanded state, as shown in FIGS. 1, 2, and 4 along a first travel path 284. For example, the first elliptical member 234 and the second elliptical member 238 include an elastic region 290, at or adjacent a major axis 292 of the first elliptical member 234 and the second elliptical member 238. The elastic region 290 allows the first elliptical member 234 and the second elliptical member 238 to travel along the first travel path 284, so as to change a length of the minor axis 276 of the first elliptical member 234 and the second elliptical member 238.



FIG. 4 illustrates one embodiment in which the elastic region 490 can include an integrated spring 496. For example, the first elliptical member 434 and the second elliptical member 438 can each include the integrated spring 496 in the valve portion 450 and the support portion 454 of the first elliptical member 434 and the second elliptical member 438. In one embodiment, the integrated spring 496 can have a circular or an elliptical coil configuration. FIGS. 5A and 5B provide additional embodiments of elastic region 590, were elastic region 590 can include a protuberance 598 in the first elliptical member 534 and the second elliptical member 538. Other shapes for the elastic region are also possible.


Referring again to FIGS. 2A and 2B, the valve frame 214 and the support frame 218 meet at the first region 242 and the second region 246. The valve frame 214 and the support frame 218 meet in the first region 242 and the second region 246 at a flexible connection joint 299. The flexible connection joint 299 allows for the support frame 218 and the valve frame 214 to travel between the collapsed state, as shown generally in FIG. 3, and the expanded state, as shown generally in FIGS. 1, 2, and 4, along a second travel path 206.


In one embodiment, the flexible connection joint 299 can include the portion of the first elliptical member 234 and the second elliptical member 238 at which the curve 274 occurs. FIG. 4 shows an additional embodiment of the flexible connection joint 499 that includes an integrated spring 410 where the support frame 418 joins to the valve frame 414 on the axis 420. The integrated spring 410 can have a circular or an elliptical coil configuration.


The first elliptical member 234 and the second elliptical member 238 can include a variety of cross-sectional shapes and dimensions. For example, cross-sectional shapes for the first elliptical member 234 and the second elliptical member 238 can include, but are not limited to, circular, tubular, I-shaped, T-shaped, oval, and triangular. The first elliptical member 234 and the second elliptical member 238 can also have a single cross-sectional shape (e.g., all of the first and second elliptical members 234 and 238 have a circular cross-sectional shape). In an additional embodiment, the first elliptical member 234 and the second elliptical member 238 can have two or more cross-sectional shapes (e.g., a circular cross-sectional shape in the elastic region 290 and a different cross-sectional shape in other regions of members 234 and 238).


Valve frame 214 and support frame 218 can further include one or more contiguous members. For example, valve frame 214 and support frame 218 can be formed from a single contiguous member that forms both the first elliptical member 234 and the second elliptical member 238. The single contiguous member can be bent around an elongate tubular mandrel to form both the valve frame 214 and the support frame 218. The ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the first elliptical member 234 and the second elliptical member 238. In an additional embodiment, the valve frame 214 and the support frame 218 of the valve can be derived (e.g., laser cut, water cut) from a single tubular segment. The first elliptical member 234 and the second elliptical member 238 can be heat set by a method as is typically known for the material which forms the members 234 and 238.


In an additional embodiment, the valve frame 214 and the support frame 218 can each be formed from separate contiguous members that are joined as described herein. For example, a first contiguous member can be used to form the first elliptical member 234 and a second contiguous member can be used to form the second elliptical member 238 that is joined to the first elliptical member 234. Methods of joining members 234 and 238 to form the valve frame 214 and the support frame 218 at the first region 242 and the second region 246 can include, but are not limited to, welding, gluing, fusing, and intertwining (e.g., coaxially intertwining the integrated springs of the valve frame 214 and the support frame 218) the members that form the valve frame 214 and the support frame 218.


The valve frame 214 and the support frame 218 can be formed from a biocompatible metal, metal alloy, polymeric material, or combinations thereof, which allow the valve frame 214 and support frame 218 to self-expand and to move radially between the collapsed and expanded state, as discussed herein. To accomplish this, the biocompatible metal, metal alloy, or polymeric material should exhibit a low elastic modulus and a high yield stress for large elastic strains that can recover from elastic deformations. Examples of suitable materials include, but are not limited to, medical grade stainless steel (e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof. In an additional embodiment, the valve frame 214 and the support frame 218 may be formed from a shape-memory material. Examples of a suitable shape-memory material include, but are not limited to, alloys of nickel and titanium in specific proportions known in the art as nitinol. Other materials are also possible.



FIG. 4 further illustrates an embodiment in which the valve frame 414 and the support frame 418 further include one or more anchoring elements. For example, the one or more anchoring elements can include, but are not limited to, one or more barbs 417 projecting from either, or both, of the valve frame 414 and the support frame 418, as shown in FIG. 4.


The valve can further include one or more radiopaque markers (e.g., tabs, sleeves, welds). For example, one or more portions of the valve frame 414, the support frame 418 and/or the barbs 417 can be formed from a radiopaque material. Radiopaque markers can be attached to and/or coated onto one or more locations along the valve frame 414, the support frame 418 and/or the barbs 417. Examples of radiopaque materials include, but are not limited to, gold, tantalum, and platinum. The position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation of the valve during its implantation.


The valve further includes valve leaflets 119 joined to valve frame 114. The valve leaflets 119 can deflect between a closed configuration (FIG. 1A) in which retrograde fluid flow through the valve 100 is restricted, and an open configuration (FIG. 1B) in which antegrade fluid flow through the valve 100 is permitted. In one embodiment, valve leaflets 119 of the valve are configured to open and close in response to the fluid motion and/or pressure differential across the valve leaflets 119.


Valve leaflets 119 include surfaces, as discussed herein, defining a reversibly sealable opening 101 for unidirectional flow of a liquid. Valve 100 shown in FIGS. 1A and 1B provide embodiments in which the surfaces defining the reversibly sealable opening 101 include a first leaflet 124 and a second leaflet 128 coupled to the valve frame 114 to provide a two-leaflet configuration (i.e., a bicuspid valve) for valve 100. Although the embodiments illustrated in FIGS. 1A and 1B of the present invention show and describe a two-leaflet configuration for valve 100, designs employing a different number of valve leaflets (e.g., tricuspid valve) are possible.


The valve leaflets 119 can have a variety of sizes and shapes. For example, each of the valve leaflets 119 (e.g., first leaflet 124 and second leaflet 128) can have a similar size and shape. In addition, each of the valve leaflets 119 can include opposed first and second major surfaces 130 and 132, respectively. Each first major surface 130 of valve leaflets 119 can be oriented to face an upstream end 140 of valve 100. Each of the valve leaflets 119 can further provide sealing surfaces 141 and 144 formed by portions of the first and the second leaflets 124 and 128, respectively, where sealing surfaces 141 and 144 can engage to define the closed configuration (FIG. 1A) of valve 100. Sealing surfaces 141 and 144 of valve leaflets 119 can separate to provide for an open configuration (FIG. 1B) of valve 100. In an additional example, each of the valve leaflets 119 need not have valve leaflets 119 that are of a similar size and shape (i.e., the valve leaflets can have a different size and shape).


Valve frame 114 can include an open frame construction (i.e., valve frame 114 defines an opening) through which valve leaflets 119 can radially-collapse and radially-expand. The valve leaflets 119 can be provided over the open frame construction of the valve frame 114 to direct fluid flow through reversibly sealable opening 101 under specific fluid flow conditions. In one embodiment, the material of the valve leaflets 119 coupled to the valve frame 114 can be sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets 119 for delivery by catheter to a location within a body lumen.


In one embodiment, each of the valve leaflets 119 includes sufficient excess material spanning valve frame 114 such that fluid pressure (e.g., antegrade flow) acting on the first major surface 130 of the valve leaflets 119 forces the valve 100 into an open configuration (FIG. 1B). Valve leaflets 119 further include arcuate edges 151 and 152 that are positioned adjacent each other along a substantially catenary curve between the first region 142 and the second region 146 in the closed configuration (FIG. 1A) of valve 100. Similarly, arcuate edges 151 and 152 can define opening 101 when the valve 100 is in the open configuration (FIG. 1B).


In an additional embodiment, in the open configuration the sufficient excess material spanning the valve frame 114 can allow the first and second major surfaces 130 and 132 to take on a semi-tubular structure 159, as shown in FIG. 1B, when fluid pressure opens the valve 100. In an additional embodiment, arcuate edge 151 and 152 of valve 100 can open to approximately the full inner diameter of body lumen 111.


Each of the second major surfaces 132 of the valve leaflets 119 can further include a curve imparted thereto so as to provide the second major surface 132 with a concave structure 164. The concave structure 164 allows the valve leaflets 119 to better collect retrograde fluid flow to urge valve leaflets 119 towards the closed configuration. For example, as retrograde flow begins, the valve leaflets 119 respond by moving towards the center of valve 100. As the valve leaflets 119 approach the center of the device the sealing surfaces 141 and 144 make sufficient contact to effectively close valve 100 and restrict retrograde fluid flow.


In an additional embodiment, the valve leaflets 119 can include one or more support structures. For example, the valve leaflets 119 can include one or more support ribs having a predetermined shape. In one embodiment, the predetermined shape of the support ribs can include a curved bias so as to provide the valve leaflets 119 with a curved configuration. Support ribs can be constructed of a flexible material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when valve leaflets 119 are urged into an open position, and stiff when the valve leaflets 119 are urged into a closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve. In an additional embodiment, support ribs can also be attached to valve frame 114 so as to impart a spring bias to the valve leaflets in either the open or the closed configuration.


The valve leaflets 119 can be constructed of a fluid-impermeable biocompatible material that can be either synthetic or biologic. Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polystyrene-polyisobutylene-polystyrene, polyurethane, segmented poly(carbonate-urethane), Dacron, polyethlylene (PE), polyethylene terephthalate (PET), silk, urethane, Rayon, Silicone, or the like. Possible biologic materials include, but are not limited to, autologous, allogeneic or xenograft material. These include explanted veins and decellularized basement membrane materials, such as small intestine submucosa (SIS) or umbilical vein.


Valve leaflets 119 can be coupled to the various embodiments of valve frame 114, as described herein, in any number of ways. For example, a variety of fasteners can be used to couple the material of the valve leaflets 119 to the valve frame 114. In one embodiment, the material of the valve leaflets 119 can be wrapped at least partially around the valve frame 114 and coupled using the fastener. Fasteners can include, but are not limited to, biocompatible staples, glues, and sutures. In an additional embodiment, valve leaflets 119 can be coupled to the various embodiments of valve frame 114 through the use of heat sealing, solvent bonding, adhesive bonding, or welding the valve leaflets 119 to either a portion of the valve leaflet 119 (i.e., itself) and/or the valve frame 114. Valve leaflets 119 can also be attached to valve frame 114 according to the methods described in U.S. Patent Application Publication US 2002/0178570 to Sogard et al., which is hereby incorporated by reference in its entirety.


The valve leaflets 119 may also be treated and/or coated with any number of surface or material treatments. For example, the valve leaflets 119, the valve frame 114, and/or the support frame 116 can be treated with a non-thrombogenic biocompatible material, as are known or will be known. In an additional example, the valve leaflets 119, the valve frame 114, and/or the support frame 116 can be treated with one or more biologically active compounds and/or materials that may promote and/or prevent endothelization of the valve leaflets 119. Similarly, each of the valve leaflets 119 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from either a donor or the host patient which are attached to the valve leaflets 119. The cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 119.


Examples of possible non-thrombogenic biocompatible material coatings include block copolymers comprising at least one A block and at least one B block. The A blocks can include soft elastomeric blocks, which are based upon one or more polyolefins, or other polymer with a glass transition temperature at or below room temperature. For example, the A blocks can be polyolefinic blocks having alternating quaternary and secondary carbons of the general formulation: —(CRR′—CH2)n—, where R and R′ are, independently, linear or branched aliphatic groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and so forth, or represent cyclic aliphatic groups such as cyclohexane, cyclopentane, and the like, either with or without pendant groups. Examples of polyolefinic blocks include polymeric blocks of isobutylene H2C═C(CH3)2, (i.e., where R and R′ are methyl groups). Other examples of A blocks include silicone rubber blocks and acrylate rubber blocks.


The B blocks can include hard thermoplastic blocks with glass transition temperatures significantly higher than the elastomeric A blocks which, when combined with the soft A blocks, are capable of, beside other things, altering or adjusting the hardness of the resulting copolymer to achieve a desired combination of qualities. Examples of B blocks include polymers of methacrylates or polymers of vinyl aromatics. More specific examples of B blocks include blocks that can be formed from monomers of styrene, styrene derivatives (e.g., α-methylstyrene, ring-alkylated styrenes or ring-halogenated styrenes or other substituted styrenes where one or more substituents are present on the aromatic ring) or mixtures of the same, collectively referred to herein as “styrenic blocks” or “polystyrenic blocks”, or can be formed from monomers of methylmethacrylate, ethylmethacrylate, hydroxyethyl methacrylate or mixtures of the same.


The block copolymers are provided in a variety of architectures, including cyclic, linear, and branched architectures. Branched architectures include star-shaped architectures (e.g., architectures in which three or more chains emanate from a single region), comb architectures (e.g., copolymers having a main chain and a plurality of side chains), and dendritic architectures (including arborescent or hyperbranched copolymers).


Some examples of such block copolymers include, but are not limited to, the following: (a) BA (linear diblock), (b) BAB or ABA (linear triblock), (c) B(AB)n or A(BA)n (linear alternating block), or (d) X-(AB)n or X-(BA)n (includes diblock, triblock and other radial block copolymers), where n is a positive whole number and X is a starting seed, or initiator, molecule. One specific group of polymers have X-(AB)n structures, which are frequently referred to as diblock copolymers and triblock copolymers where n=1 and n=2, respectively (this terminology disregards the presence of the starting seed molecule, for example, treating A-X-A as a single A block, with the triblock therefore denoted as BAB). One example of a polymer from this group includes polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS). Where n=3 or more, these structures are commonly referred to as star-shaped block copolymers. Other examples of block polymers include branched block copolymers such as dendritic block copolymers, wherein at least one of the A and B blocks is branched, for instance, where the A blocks are branched and are capped by the B blocks.



FIG. 6 illustrates one embodiment of a system 601. System 601 includes at least one of the valves, as described herein, and a catheter 608. The catheter 608 includes an elongate body 609 having a proximal end 613 and a distal end 615, where a valve 600 can be located between the proximal end 613 and distal end 615. The catheter 608 can further include a lumen 621 longitudinally extending to the distal end 615. In one embodiment, lumen 621 extends between proximal end 613 and distal end 615 of catheter 608. The catheter 608 can further include a guidewire lumen 631 that extends within the elongate body 609, were the guidewire lumen 631 can receive a guidewire for positioning the catheter 608 and the valve 600 within a body lumen (e.g., a vein of a patient).


The system 601 can further include a deployment shaft 635 positioned within lumen 621, and a sheath 639 positioned adjacent the distal end 615. In one embodiment, the valve 600 can be positioned at least partially within the sheath 639 and adjacent the deployment shaft 635. The deployment shaft 635 can be moved within the lumen 621 to deploy valve 600. For example, deployment shaft 635 can be used to push valve 600 from sheath 639 in deploying valve 600.



FIG. 7 illustrates an additional embodiment of the system 701. The catheter 708 includes elongate body 709, lumen 721, a retraction system 745 and a retractable sheath 743. The retractable sheath 743 can be positioned over at least a portion of the elongate body 709, where the retractable sheath 743 can move longitudinally along the elongate body 709. The valve 700 can be positioned at least partially within the retractable sheath 743, where the retractable sheath 743 moves along the elongate body 709 to deploy the valve 700. In one embodiment, retraction system 745 includes one or more wires coupled to the retractable sheath 743, where the wires are positioned at least partially within and extend through lumen 721 in the elongate body 709. Wires of the retraction system 745 can then be used to retract the retractable sheath 743 in deploying valve 700.


Embodiments of the present invention can further include methods of forming the valve of the present invention. For example, the methods can include forming a valve, as discussed herein. Valve can include the valve frame, the valve leaflets joined to the valve frame, where the valve leaflets includes surfaces defining a reversibly sealable opening for unidirectional flow of a liquid. Valve can further include the support frame that meets the valve frame on an axis from which the valve frame and the support frame extend in an opposing direction.


Valve can then be reversibly joined to the catheter. Reversibly joining valve to the catheter can include altering the shape of valve from a first shape, for example an expanded state, to join valve and the catheter. For example, in reversibly joining valve and the catheter, the shape of valve can be altered into the compressed state. Valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter.


In one embodiment, positioning valve at least partially within the sheath of the catheter includes positioning valve in the compressed state adjacent the deployment shaft of the catheter. In an another embodiment, the sheath of the catheter functions as a retractable sheath, where valve in the compressed state can be reversibly joined with the catheter by positioning valve at least partially within the reversible sheath of the catheter.


Embodiments of the present invention can also include positioning and deploying the valve of the present invention. For example, at least part of a catheter that includes valve can be positioned at a predetermined location. In one embodiment, the predetermined location can include a position within a body lumen of a venous system of a patient. For example, positioning at least part of the catheter at the predetermined location includes positioning at least part of the catheter within a vein of a leg.


In one embodiment, positioning the catheter that includes valve within the body lumen of a venous system includes introducing the catheter into the venous system of the patient using minimally invasive percutaneous, transluminal catheter based delivery system. For example, a guidewire can be positioned within a body lumen of a patient that includes the predetermined location. The catheter, including valve can be positioned over the guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location. In one embodiment, radiopaque markers on the catheter and/or the valve can be used to help locate and position the valve.


The valve can be deployed from the catheter at the predetermined location. In one embodiment, valve of the present invention can be deployed and placed in any number of vascular locations. For example, valve can be deployed and placed within a major vein of a patient's leg. In one embodiment, major veins include, but are not limited to, those of the peripheral venous system. Examples of veins in the peripheral venous system include, but are not limited to, the superficial veins such as the short saphenous vein and the greater saphenous vein, and the veins of the deep venous system, such as the popliteal vein and the femoral vein.


As discussed herein, the valve can be deployed from the catheter in any number of ways. For example, the catheter can include a retractable sheath in which valve can be at least partially housed. Valve can be deployed by retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location. In an additional example, the catheter can include a deployment shaft and sheath in which valve can be at least partially housed adjacent the deployment shaft. Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location.


In one embodiment, valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall. For example, the valve can be selected to have a larger expansion diameter than the diameter of the inner wall of the body lumen. This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve. As described herein, the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve. It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.


In addition, the use of both the valve frame and the support frame of valve can provide a self centering aspect to valve within a body lumen. In one embodiment, the self centering aspect resulting from the support frame, in conjunction with valve frame, may allow valve to maintain a substantially coaxial alignment with the body lumen (e.g., such as a vein) as valve leaflets deflect between the open and closed configurations so as to better seal reversible opening when valve is closed.


While the present invention has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the spirit and scope of the invention. As such, that which is set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined by the following claims, along with the full range of equivalents to which such claims are entitled.


In addition, one of ordinary skill in the art will appreciate upon reading and understanding this disclosure that other variations for the invention described herein can be included within the scope of the present invention.


In the foregoing Detailed Description, various features are grouped together in several embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the embodiments of the invention require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.

Claims
  • 1. A valve, comprising: a valve frame;a valve leaflet joined to the valve frame, where the valve leaflet includes surfaces defining a reversibly sealable opening extending between a first region and a second region for unidirectional flow of a liquid; anda support frame, where the support frame meets the valve frame at the first region and the second region on an axis that extends across and parallel with the reversibly sealable opening of the valve leaflet, and where the valve frame and the support frame extend from the axis in an opposing direction;where the valve frame and the support frame include a first elliptical member and a second elliptical member that meet at the first region and the second region opposite the first region on the axis; andwhere each of the first elliptical member and the second elliptical member include both a valve portion extending from the first region and the second region to form the valve frame, and a support portion extending from the first region and the second region in the opposing direction to form the support frame.
  • 2. The valve of claim 1, where the valve portion includes the valve leaflet and a portion of both the first elliptical member and the second elliptical member, and the support portion includes a portion of both the first elliptical member and the second elliptical member.
  • 3. The valve of claim 1, where the valve leaflet includes a first leaflet and a second leaflet attached to the valve frame, the first leaflet and the second leaflet including a surface with a semi-tubular structure when fluid opens the reversibly sealable opening and a concave structure when fluid closes the reversibly sealable opening.
  • 4. The valve of claim 1 further comprising, a flexible joint at the first region and the second region.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 10/741,995, filed Dec. 19, 2003, of which is herein incorporated by reference.

US Referenced Citations (634)
Number Name Date Kind
3671979 Moulopoulos Jun 1972 A
4291420 Reul Sep 1981 A
4787901 Baykut Nov 1988 A
4872874 Taheri Oct 1989 A
4935030 Alonso Jun 1990 A
4994077 Dobben Feb 1991 A
5002567 Bona et al. Mar 1991 A
5141491 Bowald Aug 1992 A
5163953 Vince Nov 1992 A
5219355 Parodi et al. Jun 1993 A
5254127 Wholey et al. Oct 1993 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5358518 Camilli Oct 1994 A
5370685 Stevens Dec 1994 A
5411552 Anderson et al. May 1995 A
5469868 Reger Nov 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5643208 Parodi Jul 1997 A
5693087 Parodi Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5735859 Fischell et al. Apr 1998 A
5741326 Solovay Apr 1998 A
5741333 Frid Apr 1998 A
5800506 Perouse Sep 1998 A
5824061 Quijano et al. Oct 1998 A
5879320 Cazenave Mar 1999 A
5895419 Tweden et al. Apr 1999 A
5910170 Reimink et al. Jun 1999 A
6010531 Donlon et al. Jan 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6092529 Cox Jul 2000 A
6139575 Shu et al. Oct 2000 A
6200336 Pavcnik et al. Mar 2001 B1
6287334 Moll et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6312447 Grimes Nov 2001 B1
6315793 Bokros et al. Nov 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6451054 Stevens Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461366 Seguin Oct 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6562069 Cai et al. May 2003 B2
6564805 Garrison et al. May 2003 B2
6569196 Vesely May 2003 B1
6585761 Taheri Jul 2003 B2
6602286 Strecker Aug 2003 B1
6605112 Moll et al. Aug 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6635085 Caffey et al. Oct 2003 B1
6666885 Moe Dec 2003 B2
6666886 Tranquillo et al. Dec 2003 B1
6669725 Scott Dec 2003 B2
6673109 Cox Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6676702 Mathis Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6692512 Jang Feb 2004 B2
6695866 Kuehn et al. Feb 2004 B1
6695878 McGuckin, Jr. et al. Feb 2004 B2
6709456 Langberg et al. Mar 2004 B2
6709457 Otte et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B2
6716244 Klaco Apr 2004 B2
6719767 Kimblad Apr 2004 B1
6719784 Henderson Apr 2004 B2
6719786 Ryan et al. Apr 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6719790 Brendzel et al. Apr 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6723122 Yang et al. Apr 2004 B2
6723123 Kazatchkov et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6726716 Marquez Apr 2004 B2
6726717 Alfieri et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6730122 Pan et al. May 2004 B1
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6749630 McCarthy et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6752828 Thornton Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6761734 Suhr Jul 2004 B2
6761735 Eberhardt et al. Jul 2004 B2
6764494 Menz et al. Jul 2004 B2
6764508 Roehe et al. Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6770083 Seguin Aug 2004 B2
6780200 Jansen Aug 2004 B2
6786924 Ryan et al. Sep 2004 B2
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790231 Liddicoat et al. Sep 2004 B2
6793673 Kowalsky et al. Sep 2004 B2
6797000 Simpson et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6802860 Cosgrove et al. Oct 2004 B2
6805710 Bolling et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6810882 Langberg et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824562 Mathis et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B2
6840246 Downing Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6846324 Stobie Jan 2005 B2
6846325 Liddicoat Jan 2005 B2
6858039 McCarthy Feb 2005 B2
6869444 Gabbay Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875224 Grimes Apr 2005 B2
6875230 Morita et al. Apr 2005 B1
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6881224 Kruse et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6890352 Lentell May 2005 B1
6890353 Cohn et al. May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896700 Lu et al. May 2005 B2
6902576 Drasler et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6913608 Liddicoat et al. Jul 2005 B2
6916338 Speziali Jul 2005 B2
6918917 Nguyen et al. Jul 2005 B1
6921407 Nguyen et al. Jul 2005 B2
6921811 Zamora et al. Jul 2005 B2
6926715 Hauck et al. Aug 2005 B1
6926730 Nguyen et al. Aug 2005 B1
6929653 Strecter Aug 2005 B2
6932838 Schwartz et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939359 Tu et al. Sep 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6945957 Freyman Sep 2005 B2
6945978 Hyde Sep 2005 B1
6945996 Sedransk Sep 2005 B2
6945997 Huynh et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6951573 Dilling Oct 2005 B1
6955689 Ryan et al. Oct 2005 B2
6958076 Acosta et al. Oct 2005 B2
6962605 Cosgrove et al. Nov 2005 B2
6964682 Nguyen-Thien-Nhon et al. Nov 2005 B2
6964683 Kowalsky et al. Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6966925 Stobie Nov 2005 B2
6966926 Mathis Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976995 Mathis et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6986775 Morales et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6997950 Chawla Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7007396 Rudko et al. Mar 2006 B2
7011669 Kimblad Mar 2006 B2
7011681 Vesely Mar 2006 B2
7011682 Lahsinski et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018407 Wright et al. Mar 2006 B1
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025780 Gabbay Apr 2006 B2
7033390 Johnson et al. Apr 2006 B2
7037333 Myers et al. May 2006 B2
7037334 Hlavka et al. May 2006 B1
7041128 McGuckin, Jr. et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7044967 Solem et al. May 2006 B1
7048754 Martin et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7052487 Cohn et al. May 2006 B2
7052507 Wakuda et al. May 2006 B2
7063722 Marquez Jun 2006 B2
7066954 Ryan et al. Jun 2006 B2
7070616 Majercak et al. Jul 2006 B2
7077862 Vidlund et al. Jul 2006 B2
7081131 Thornton Jul 2006 B2
7087064 Hyde Aug 2006 B1
7089051 Jäverud et al. Aug 2006 B2
7090695 Solem et al. Aug 2006 B2
20010011187 Pavcnik et al. Aug 2001 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020026216 Grimes Feb 2002 A1
20020082630 Menz et al. Jun 2002 A1
20020123802 Snyders Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20020178570 Sogard et al. Dec 2002 A1
20020183835 Taylor et al. Dec 2002 A1
20020183838 Liddicoat et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030050694 Yang et al. Mar 2003 A1
20030055492 Shaolian et al. Mar 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030163194 Quijano et al. Aug 2003 A1
20030167071 Martin et al. Sep 2003 A1
20030171806 Mathis et al. Sep 2003 A1
20030199975 Gabbay Oct 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20030229395 Cox Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236569 Mathis et al. Dec 2003 A1
20040002719 Oz et al. Jan 2004 A1
20040003819 St. Goar et al. Jan 2004 A1
20040010305 Alferness et al. Jan 2004 A1
20040015230 Moll et al. Jan 2004 A1
20040015232 Shu et al. Jan 2004 A1
20040015233 Jansen Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040019377 Taylor et al. Jan 2004 A1
20040019378 Hlavka et al. Jan 2004 A1
20040024447 Haverich Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040030321 Fangrow, Jr. Feb 2004 A1
20040030381 Shu Feb 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040030405 Carpentier et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040039443 Solem et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044365 Bachman Mar 2004 A1
20040044403 Bischoff et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059351 Eigler et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040059412 Lytle, IV et al. Mar 2004 A1
20040060161 Leal et al. Apr 2004 A1
20040073301 Donlon et al. Apr 2004 A1
20040073302 Rourke et al. Apr 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040082923 Field Apr 2004 A1
20040082991 Nguyen et al. Apr 2004 A1
20040087975 Lucatero et al. May 2004 A1
20040088045 Cox May 2004 A1
20040088046 Speziali May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093080 Helmus et al. May 2004 A1
20040097979 Svanidze et al. May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102839 Cohn et al. May 2004 A1
20040102840 Solem et al. May 2004 A1
20040102842 Jansen May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040106991 Hopkins et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040122512 Navia et al. Jun 2004 A1
20040122513 Navia et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122515 Chu Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127980 Kowalsky et al. Jul 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133267 Lane Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040153052 Mathis Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040153147 Mathis Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040167539 Keuhn et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040176840 Langberg et al. Sep 2004 A1
20040181238 Zarbatany et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186561 McGuckin, Jr. et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193253 Thorpe et al. Sep 2004 A1
20040193260 Alferness et al. Sep 2004 A1
20040199155 Mollenauer Oct 2004 A1
20040199183 Oz et al. Oct 2004 A1
20040199191 Schwartz Oct 2004 A1
20040204758 Eberhardt et al. Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210303 Sedransk Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220654 Mathis et al. Nov 2004 A1
20040220657 Nieminen et al. Nov 2004 A1
20040225322 Garrison et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Case et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230297 Thornton Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040243153 Liddicoat et al. Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243228 Kowalsky et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040249452 Adams et al. Dec 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260276 Rudko et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050004583 Oz et al. Jan 2005 A1
20050004667 Swinford et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050027351 Reuter et al. Feb 2005 A1
20050027353 Alferness et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033419 Alferness et al. Feb 2005 A1
20050033446 Deem et al. Feb 2005 A1
20050038506 Webler et al. Feb 2005 A1
20050038507 Alferness et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
20050049679 Taylor et al. Mar 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050049697 Sievers Mar 2005 A1
20050054977 Laird et al. Mar 2005 A1
20050055079 Duran Mar 2005 A1
20050055087 Starksen Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065460 Laird Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050065594 Dimatteo et al. Mar 2005 A1
20050065597 Lansac Mar 2005 A1
20050070998 Rourke et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075659 Realyvasquez et al. Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075713 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075723 Schroeder et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075729 Nguyen et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080483 Solem et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050085903 Lau Apr 2005 A1
20050085904 Lemmon Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096739 Cao May 2005 A1
20050096740 Langberg et al. May 2005 A1
20050101975 Nguyen et al. May 2005 A1
20050102026 Turner et al. May 2005 A1
20050107810 Morales et al. May 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119673 Gordon et al. Jun 2005 A1
20050119734 Spence et al. Jun 2005 A1
20050119735 Spence et al. Jun 2005 A1
20050125011 Spence et al. Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137449 Nieminen et al. Jun 2005 A1
20050137450 Aronson et al. Jun 2005 A1
20050137451 Gordon et al. Jun 2005 A1
20050137676 Richardson et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137685 Nieminen et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137700 Spence et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050143810 Dauner et al. Jun 2005 A1
20050143811 Realyvasquez Jun 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149179 Mathis et al. Jul 2005 A1
20050149180 Mathis et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050159810 Filsoufi Jul 2005 A1
20050159811 Lane Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165478 Song Jul 2005 A1
20050171472 Lutter Aug 2005 A1
20050171601 Cosgrove et al. Aug 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050184122 Hlavka et al. Aug 2005 A1
20050187614 Agnew Aug 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050187617 Navia Aug 2005 A1
20050192606 Paul, Jr. et al. Sep 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216039 Lederman Sep 2005 A1
20050216077 Mathis et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050222675 Sauter Oct 2005 A1
20050222678 Lashinski et al. Oct 2005 A1
20050228422 Machold et al. Oct 2005 A1
20050228479 Pavcnik et al. Oct 2005 A1
20050228486 Case et al. Oct 2005 A1
20050228494 Marquez Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228496 Mensah et al. Oct 2005 A1
20050234541 Hunt et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050240255 Schaeffer Oct 2005 A1
20050240259 Sisken et al. Oct 2005 A1
20050240262 White Oct 2005 A1
20050244460 Alferiev et al. Nov 2005 A1
20050246013 Gabbay Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050261704 Mathis Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267493 Schreck et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267565 Dave et al. Dec 2005 A1
20050267571 Spence et al. Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050267574 Cohn et al. Dec 2005 A1
20050272969 Alferness et al. Dec 2005 A1
20050273160 Lashinski et al. Dec 2005 A1
20050278015 Dave et al. Dec 2005 A1
20050283178 Flagle et al. Dec 2005 A1
20050288779 Shaoulian et al. Dec 2005 A1
20060000715 Whitcher et al. Jan 2006 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060009842 Huynh et al. Jan 2006 A1
20060013805 Hebbel et al. Jan 2006 A1
20060013855 Carpenter et al. Jan 2006 A1
20060015136 Besselink Jan 2006 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060020335 Kowalsky et al. Jan 2006 A1
20060020336 Liddicoat Jan 2006 A1
20060025750 Starksen et al. Feb 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025856 Ryan et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030747 Kantrowitz et al. Feb 2006 A1
20060030866 Schreck Feb 2006 A1
20060030882 Adams et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060036317 Vidlund et al. Feb 2006 A1
20060041305 Lauterjung Feb 2006 A1
20060041306 Vidlund et al. Feb 2006 A1
20060047297 Case Mar 2006 A1
20060047338 Jenson Mar 2006 A1
20060047343 Oviatt et al. Mar 2006 A1
20060052804 Mialhe Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058889 Case et al. Mar 2006 A1
20060064115 Allen et al. Mar 2006 A1
20060064116 Allen et al. Mar 2006 A1
20060064118 Kimblad Mar 2006 A1
20060064174 Zadno Mar 2006 A1
20060069400 Burnett et al. Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060074483 Schrayer Apr 2006 A1
20060074484 Huber Apr 2006 A1
20060074485 Realyvasquez Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060089708 Osse et al. Apr 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060095125 Chinn et al. May 2006 A1
20060099326 Keogh et al. May 2006 A1
20060100697 Casanova May 2006 A1
20060100699 Vidlund et al. May 2006 A1
20060106278 Machold et al. May 2006 A1
20060106279 Machold et al. May 2006 A1
20060106456 Machold et al. May 2006 A9
20060111660 Wolf et al. May 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060111774 Samkov et al. May 2006 A1
20060116572 Case Jun 2006 A1
20060116756 Solem et al. Jun 2006 A1
20060122686 Gilad et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060127443 Helmus Jun 2006 A1
20060129235 Seguin et al. Jun 2006 A1
20060129236 McCarthy Jun 2006 A1
20060135476 Kutryk et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060135967 Realyvasquez Jun 2006 A1
20060136044 Osborne Jun 2006 A1
20060136045 Flagle et al. Jun 2006 A1
20060136052 Vesely Jun 2006 A1
20060136054 Berg et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060142847 Shaknovich Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060142854 Alferness et al. Jun 2006 A1
20060149358 Zilla et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060149367 Sieracki Jul 2006 A1
20060149368 Spence Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060161250 Shaw Jul 2006 A1
20060167468 Gabbay Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060167542 Quintessenza Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
Foreign Referenced Citations (166)
Number Date Country
0 380 666 Aug 1990 EP
0 466 518 Jan 1992 EP
0667133 Aug 1995 EP
2 728 457 Jun 1996 FR
WO 2004060217 Jul 2004 WF
WO 8800459 Jan 1988 WO
WO 9015582 Dec 1990 WO
WO 9619159 Jun 1996 WO
WO 9846115 Oct 1998 WO
WO 9904724 Feb 1999 WO
WO 0067679 Nov 2000 WO
WO 0117462 Mar 2001 WO
WO 0241764 May 2002 WO
WO 03047468 Jun 2003 WO
WO 03084443 Oct 2003 WO
WO 2004016200 Feb 2004 WO
WO 2004019825 Mar 2004 WO
WO 2004021893 Mar 2004 WO
WO 2004023980 Mar 2004 WO
WO 2004030568 Apr 2004 WO
WO 2004030569 Apr 2004 WO
WO 2004030570 Apr 2004 WO
WO 2004032724 Apr 2004 WO
WO 2004032796 Apr 2004 WO
WO 2004037128 May 2004 WO
WO 2004037317 May 2004 WO
WO 2004039432 May 2004 WO
WO 2004043265 May 2004 WO
WO 2004043273 May 2004 WO
WO 2004043293 May 2004 WO
WO 2004045370 Jun 2004 WO
WO 2004045378 Jun 2004 WO
WO 2004045463 Jun 2004 WO
WO 2004047677 Jun 2004 WO
WO 2004060470 Jul 2004 WO
WO 2004062725 Jul 2004 WO
WO 2004066803 Aug 2004 WO
WO 2004066826 Aug 2004 WO
WO 2004069287 Aug 2004 WO
WO 2004075789 Sep 2004 WO
WO 2004080352 Sep 2004 WO
WO 2004082523 Sep 2004 WO
WO 2004082527 Sep 2004 WO
WO 2004082528 Sep 2004 WO
WO 2004082536 Sep 2004 WO
WO 2004082537 Sep 2004 WO
WO 2004082538 Sep 2004 WO
WO 2004082757 Sep 2004 WO
WO 2004084746 Oct 2004 WO
WO 2004084770 Oct 2004 WO
WO 2004089246 Oct 2004 WO
WO 2004089250 Oct 2004 WO
WO 2004089253 Oct 2004 WO
WO 2004091449 Oct 2004 WO
WO 2004091454 Oct 2004 WO
WO 2004093638 Nov 2004 WO
WO 2004093726 Nov 2004 WO
WO 2004093728 Nov 2004 WO
WO 2004093730 Nov 2004 WO
WO 2004093745 Nov 2004 WO
WO 2004093935 Nov 2004 WO
WO 2004096100 Nov 2004 WO
WO 2004103222 Dec 2004 WO
WO 2004103223 Dec 2004 WO
WO 2004105584 Dec 2004 WO
WO 2004105651 Dec 2004 WO
WO 2004112582 Dec 2004 WO
WO 2004112585 Dec 2004 WO
WO 2004112643 Dec 2004 WO
WO 2004112652 Dec 2004 WO
WO 2004112657 Dec 2004 WO
WO 2004112658 Dec 2004 WO
WO 2005000152 Jan 2005 WO
WO 2005002424 Jan 2005 WO
WO 2005002466 Jan 2005 WO
WO 2005004753 Jan 2005 WO
WO 2005007017 Jan 2005 WO
WO 2005007018 Jan 2005 WO
WO 2005007036 Jan 2005 WO
WO 2005007037 Jan 2005 WO
WO 2005009285 Feb 2005 WO
WO 2005009286 Feb 2005 WO
WO 2005009505 Feb 2005 WO
WO 2005009506 Feb 2005 WO
WO 2005011473 Feb 2005 WO
WO 2005011534 Feb 2005 WO
WO 2005011535 Feb 2005 WO
WO 2005013860 Feb 2005 WO
WO 2005018507 Mar 2005 WO
WO 2005021063 Mar 2005 WO
WO 2005023155 Mar 2005 WO
WO 2005025644 Mar 2005 WO
WO 2005027790 Mar 2005 WO
WO 2005027797 Mar 2005 WO
WO 2005034812 Apr 2005 WO
WO 2005039428 May 2005 WO
WO 2005039452 May 2005 WO
WO 2005046488 May 2005 WO
WO 2005046528 May 2005 WO
WO 2005046529 May 2005 WO
WO 2005046530 May 2005 WO
WO 2005046531 May 2005 WO
WO 2005048883 Jun 2005 WO
WO 2005049103 Jun 2005 WO
WO 2005051226 Jun 2005 WO
WO 2005055811 Jun 2005 WO
WO 2005055883 Jun 2005 WO
WO 2005058206 Jun 2005 WO
WO 2005065585 Jul 2005 WO
WO 2005065593 Jul 2005 WO
WO 2005065594 Jul 2005 WO
WO 2005070342 Aug 2005 WO
WO 2005070343 Aug 2005 WO
WO 2005072654 Aug 2005 WO
WO 2005072655 Aug 2005 WO
WO 2005079706 Sep 2005 WO
WO 2005082288 Sep 2005 WO
WO 2005082289 Sep 2005 WO
WO 2005084595 Sep 2005 WO
WO 2005087139 Sep 2005 WO
WO 2005087140 Sep 2005 WO
WO 2006000763 Jan 2006 WO
WO 2006000776 Jan 2006 WO
WO 2006002492 Jan 2006 WO
WO 2006004679 Jan 2006 WO
WO 2006005015 Jan 2006 WO
WO 2006009690 Jan 2006 WO
WO 2006011127 Feb 2006 WO
WO 2006012011 Feb 2006 WO
WO 2006012013 Feb 2006 WO
WO 2006012038 Feb 2006 WO
WO 2006012068 Feb 2006 WO
WO 2006012322 Feb 2006 WO
WO 2006019498 Feb 2006 WO
WO 2006026371 Mar 2006 WO
WO 2006026377 Mar 2006 WO
WO 2006026912 Mar 2006 WO
WO 2006027499 Mar 2006 WO
WO 2006028821 Mar 2006 WO
WO 2006029062 Mar 2006 WO
WO 2006031436 Mar 2006 WO
WO 2006031469 Mar 2006 WO
WO 2006032051 Mar 2006 WO
WO 2006034245 Mar 2006 WO
WO 2006035415 Apr 2006 WO
WO 2006041505 Apr 2006 WO
WO 2006044679 Apr 2006 WO
WO 2006048664 May 2006 WO
WO 2006050459 May 2006 WO
WO 2006050460 May 2006 WO
WO 2006054107 May 2006 WO
WO 2006054930 May 2006 WO
WO 2006055982 May 2006 WO
WO 2006060546 Jun 2006 WO
WO 2006063108 Jun 2006 WO
WO 2006063181 Jun 2006 WO
WO 2006063199 Jun 2006 WO
WO 2006064490 Jun 2006 WO
WO 2006065212 Jun 2006 WO
WO 2006065930 Jun 2006 WO
WO 2006066148 Jun 2006 WO
WO 2006066150 Jun 2006 WO
WO 2006069094 Jun 2006 WO
WO 2006070372 Jul 2006 WO
WO 2006073628 Jul 2006 WO
WO 2006076890 Jul 2006 WO
Related Publications (1)
Number Date Country
20110060405 A1 Mar 2011 US
Divisions (1)
Number Date Country
Parent 10741995 Dec 2003 US
Child 12943238 US